LONA — LeonaBio, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1620463 ·
Last close
$2.76
Market Cap
$26.00M
52W High
$14.21
52W Low
$2.21
ADV30
77,621
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -21,878,000 -21,164,000 38,136,000 16,336,000 22,119,000
Jun 2026 0 — -19,278,000 -19,007,000 56,894,000 32,323,000 23,299,000
Mar 2026 0 — -18,143,000 -32,948,000 71,590,000 32,833,000 22,287,000
Dec 2025 0 — -10,477,000 -82,889,000 92,151,000 69,276,000 64,361,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-61,926,000
Investing CF
$-8,190,000
Financing CF
$82,437,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.99
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-563,710,000
Inventory
—
Receivables
—
ST Investments
$18,744,000
EBIT TTM
$-54,772,000
Pretax Income TTM
$-141,455,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -34,178,000 -105,609,000 92,151,000 64,361,000 27,790,000 -45,729,000
Dec 2024 0 -96,775,000 -96,940,000 58,779,000 13,938,000 44,841,000 -97,170,000
Dec 2023 0 -126,937,000 -117,672,000 160,245,000 30,057,000 130,188,000 -100,753,000
Dec 2022 0 -88,855,000 -95,639,000 258,153,000 23,016,000 235,137,000 -72,469,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$60,859,000
NetIncome TTM
$-141,455,000
OpCashFlow TTM
—
Assets (Latest)
$56,894,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
PTHS Pelthos Therapeutics Inc. $26.89M $6.84 —
EVAX Evaxion A/S $25.08M $2.78 —
SAEN Genenta Science S.p.A. $27.82M $0.58 —
MGX Metagenomi Therapeutics, Inc. $23.86M $0.63 —
ZIVO Zivo Bioscience, Inc. $23.18M $5.50 —

News headlines (Yahoo Finance, 1h cache)

LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 21:05 · Yahoo
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
2026-09-03 11:00 · Yahoo
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
2026-08-17 12:26 · Yahoo
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 20:05 · Yahoo
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
2026-08-12 11:00 · Yahoo
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
2026-06-04 11:00 · Yahoo
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 20:05 · Yahoo
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
2026-05-27 11:00 · Yahoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
2026-05-07 13:20 · Yahoo
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
2026-04-23 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.